SCHEMBL26098832

SCHEMBL26098832

COc1cc2c(-c3ccc(NC(=O)Cc4ccc(Cl)nc4)cc3)ncnc2cc1OCC1CCNCC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 3/20 0.49
▸ KDR P35968 10/20 0.47
▸ FLT4 P35916 9/20 0.47
▸ EGFR P00533 4/20 0.47
▸ FGFR1 P11362 4/20 0.47
▸ FLT1 P17948 4/20 0.47
▸ AXL P30530 1/20 0.45
▸ TYRO3 Q06418 1/20 0.45
▸ MERTK Q12866 1/20 0.45
▸ EPHA2 P29317 4/20 0.44
▸ EPHB4 P54760 4/20 0.44
▸ ERBB2 P04626 1/20 0.44
▸ RAF1 P04049 1/20 0.43
▸ PDGFRB P09619 6/20 0.42
▸ FLT3 P36888 5/20 0.42
▸ CSF1R P07333 1/20 0.42
▸ AURKA O14965 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26099624 0.89 KIT (0.47) KITKDRFLT4EGFREPHA2
SCHEMBL30394321 0.89 KIT (0.47) KITKDRFLT4EGFRFGFR1
SCHEMBL29238236 0.89 KIT (0.47) KITKDRFLT4EGFRFGFR1
SCHEMBL26102091 0.87 PDGFRB (0.48) KITKDREGFRPDGFRBAURKA
SCHEMBL30891790 0.87 KDR (0.46) KITKDRFLT4EGFRFGFR1
SCHEMBL26102350 0.87 KDR (0.46) KITKDRFLT4EGFRFGFR1
SCHEMBL26536043 0.87 KDR (0.46) KITKDRFLT4EGFRFGFR1
SCHEMBL26535078 0.87 KIT (0.57) KITKDRFLT4EGFRFGFR1
SCHEMBL26535255 0.85 PDGFRB (0.47) KITKDRFLT4EGFRFGFR1
SCHEMBL30394312 0.84 KDR (0.47) KITKDRFLT4EGFRFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US claimed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP claimed
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 — — CN claimed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO claimed
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US disclosed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP disclosed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF PDGFRA, KIT, PDGFRB KIT 2/4885KDR 5/4885FLT4 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback